| Identification | Back Directory | [Name]
Acumapimod (BCT-197) | [CAS]
836683-15-9 | [Synonyms]
CS-2801
BCT-197
Acumapimod (BCT-197)
3-(5-Amino-4-(3-cyanobenzoyl)pyrazol-1-yl)-N-cyclopropyl-4-methylbenzamide
Benzamide, 3-[5-amino-4-(3-cyanobenzoyl)-1H-pyrazol-1-yl]-N-cyclopropyl-4-methyl- | [EINECS(EC#)]
604-604-1 | [Molecular Formula]
C22H19N5O2 | [MDL Number]
MFCD28902244 | [MOL File]
836683-15-9.mol | [Molecular Weight]
385.42 |
| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:50.0(Max Conc. mg/mL);129.73(Max Conc. mM) | [form ]
A crystalline solid | [color ]
White to off-white | [InChI]
InChI=1S/C22H19N5O2/c1-13-5-6-16(22(29)26-17-7-8-17)10-19(13)27-21(24)18(12-25-27)20(28)15-4-2-3-14(9-15)11-23/h2-6,9-10,12,17H,7-8,24H2,1H3,(H,26,29) | [InChIKey]
VGUSQKZDZHAAEE-UHFFFAOYSA-N | [SMILES]
C(NC1CC1)(=O)C1=CC=C(C)C(N2C(N)=C(C(=O)C3=CC=CC(C#N)=C3)C=N2)=C1 |
| Hazard Information | Back Directory | [Uses]
Acumapimod (BCT197) is an orally active p38 MAP kinase inhibitor, with an IC50 of less than 1 μM for p38α. | [in vivo]
Acumapimod is an oral low-molecular-weight p38 inhibitor currently in development for the treatment of several inflammatory conditions, including chronic obstructive pulmonary disease (COPD). Intermittent short-term dosing of Acumapimod (75 mg on days 1 and 6) shows a marked improvement in lung function in COPD patients[2]. | [storage]
Store at -20°C | [References]
[1] Norman P, et al. Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2015 Mar;24(3):383-92. DOI:10.1517/13543784.2014.918604
[2] De Buck S, et al. Population PK-PD Model for Tolerance Evaluation to the p38 MAP Kinase Inhibitor BCT197. CPT Pharmacometrics Syst Pharmacol. 2015 Dec;4(12):691-700. DOI:10.1002/psp4.12037 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|